Sorafenib

zinc fingers and homeoboxes 2 ; Homo sapiens







201 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
101 22846973 Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells. 2012 1
102 22941289 The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib. 2012 Oct 2
103 22962324 Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma. 2012 Nov 2
104 23099651 Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. 2012 Dec 1
105 23227538 [Advances in the study of structural modifications of multi-target anticancer drug sorafenib]. 2012 Sep 1
106 23231599 Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma. 2012 Dec 11 1
107 20443129 Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. 2011 Jan 1
108 20552299 Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report. 2011 Dec 1
109 20803231 The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication. 2011 Mar 2
110 20821331 Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. 2011 Jul 1
111 20926530 Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E. 2011 Jan 1
112 20944654 The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. 2011 Feb 1
113 21079155 Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. 2011 Jan 20 2
114 21098323 Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. 2011 Jan 1 1
115 21192261 RAF inhibition and induction of cutaneous squamous cell carcinoma. 2011 Mar 2
116 21224376 Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. 2011 Mar 1 1
117 21289252 Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. 2011 Apr 2
118 21487053 Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. 2011 Jun 1
119 21529991 Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. 2011 Nov 1
120 21531053 Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. 2011 Jul 2
121 21689083 Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation. 2011 Feb 3
122 21734462 c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. 2011 Sep 15 2
123 21816375 Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. 2011 Aug 1
124 21905615 [Advances in clinical treatment of malignant melanoma: B-RAF kinase inhibition]. 2011 1
125 22174910 Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 2011 2
126 22179180 Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. 2011 Dec 3
127 19554262 Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib. 2010 Oct 1
128 19890601 Medical treatments: in association or alone, their roles and their future perspectives: the Western experience. 2010 Jul 1
129 19935717 Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. 2010 Feb 25 3
130 20078249 Toxicity of sorafenib: clinical and molecular aspects. 2010 Mar 1
131 20149262 Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study. 2010 Feb 12 2
132 20149658 Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines. 2010 Mar 1 1
133 20197396 Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. 2010 Mar 2
134 20301194 Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways. 2010 Jul 2
135 20432459 Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells. 2010 Aug 1
136 20698202 Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China. 2010 May-Jun 1
137 20810616 Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. 2010 Nov 2
138 20812347 Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway. 2010 Dec 1 2
139 20944096 Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas. 2010 Sep 1
140 21102438 AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade. 2010 Dec 1
141 21187475 PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. 2010 Dec 4
142 21351273 Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. 2010 Dec 15 2
143 24367212 Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma. 2010 Nov 2 1
144 19255327 Phase II trial of sorafenib in metastatic thyroid cancer. 2009 Apr 1 2
145 19296866 Protein kinase inhibitors: contributions from structure to clinical compounds. 2009 Feb 1
146 19436197 Sorafenib tosylate in advanced kidney cancer: past, present and future. 2009 Jul 1
147 19633425 Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. 2009 Sep 4
148 19652055 Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. 2009 Sep 10 1
149 19660024 Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. 2009 Nov 1
150 19667065 Identification of novel in vivo phosphorylation sites of the human proapoptotic protein BAD: pore-forming activity of BAD is regulated by phosphorylation. 2009 Oct 9 2